Re-formulation of microbicidal lubricants will help protect from HIV

Mar 07, 2011

Microbicides can be used to protect against HIV, and other sexually transmitted diseases, either on their own or with the added protection of a condom. New research published by BioMed Central's open access journal AIDS Research and Therapy has investigated the use of lubricants, originally designed for vaginal application, and has developed and tested new, rectal specific, formulations.

Unprotected sex is one of the major ways that HIV spreads through the population. However most research has focused on the production of vaginal microbicides which, due to differences in pH, native bacterial populations (microflora), and thickness of the epithelium, may not be safe as rectal microbicides. Researchers at the Magee Woman's Research Institute, University of Pittsburgh, have shown that some and silicone-based , but not the water-based ones they tested, significantly weakened the integrity of condoms making them more likely to break.

With this in mind Prof. Rohan's group has formulated four different lubricants, both water and lipid based, and in different formats, as a fluid or gel, which are currently being tested in clinical trials. Prof. Rohan said, "This is the first stage in the production of targeted microbicidal products. If successful these lubricants will provide a basis for the inclusion of different types of antibiotics, , and other drugs. Once completed these products will help reduce the incidence of sexually transmitted disease and bring hope in the fight to stop the spread of .

Explore further: Point-of-care CD4 testing is economically feasible for HIV care in resource-limited areas

More information: Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations, Lin Wang, Roger L Schnaare, Charlene Dezzutti, Peter A. Anton, and Lisa C. Rohan, AIDS Research and Therapy (in press)

add to favorites email to friend print save as pdf

Related Stories

Researchers reformulate tenofovir vaginal gel for rectal use

Feb 28, 2011

A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests research presented today at the 18th Conference on Retroviruses and Opportunistic Infections ...

Recommended for you

The genetics of coping with HIV

5 hours ago

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

Puerto Rico partners on US HIV vaccine project

Sep 10, 2014

Puerto Rico's governor says the island's largest public university is partnering with federal agencies to oversee a U.S.-funded project aimed at trying to develop a prophylactic vaccine for the HIV virus that causes AIDS.

User comments : 0